Biosite plans further data as FDA panel rejects heart test
This article was originally published in Clinica
Executive Summary
Rapid test manufacturer Biosite Diagnostics has said it could file an amended PMA for US approval of its Triage BNP diagnostic for heart failure as early as late summer. The company's original application was rejected by an FDA advisory panel on March 24 by six votes to three after "major concerns" with the clinical data from US trials. The agency normally follows its panel's advice.
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.